Naturhouse Health Toekomstige groei

Future criteriumcontroles 2/6

Naturhouse Health zal naar verwachting groeien in winst en omzet met respectievelijk 2.3% en 2% per jaar. De winst per aandeel zal naar verwachting groeien met 1.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 33.1% zijn.

Belangrijke informatie

2.3%

Groei van de winst

1.4%

Groei van de winst per aandeel

Specialty Retail winstgroei	14.4%
Inkomstengroei	2.0%
Toekomstig rendement op eigen vermogen	33.1%
Dekking van analisten	Low
Laatst bijgewerkt	01 Oct 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Can Mixed Fundamentals Have A Negative Impact on Naturhouse Health, S.A. (BME:NTH) Current Share Price Momentum?

Mar 06

A Look At The Intrinsic Value Of Naturhouse Health, S.A. (BME:NTH)

Jan 14

Would Shareholders Who Purchased Naturhouse Health's (BME:NTH) Stock Five Years Be Happy With The Share price Today?

Dec 01

Winst- en omzetgroeiprognoses

BME:NTH - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	52	10	10	14	1
12/31/2025	51	10	9	14	1
12/31/2024	50	10	10	14	1
6/30/2024	50	10	15	15	N/A
3/31/2024	50	11	17	18	N/A
12/31/2023	50	11	20	21	N/A
9/30/2023	50	11	16	16	N/A
6/30/2023	51	10	11	11	N/A
3/31/2023	51	10	9	9	N/A
12/31/2022	52	10	6	7	N/A
9/30/2022	54	11	9	10	N/A
6/30/2022	56	12	12	12	N/A
3/31/2022	58	13	N/A	N/A	N/A
12/31/2021	58	13	16	16	N/A
9/30/2021	57	13	N/A	N/A	N/A
6/30/2021	59	14	21	21	N/A
3/31/2021	53	10	N/A	N/A	N/A
12/31/2020	55	9	14	15	N/A
9/30/2020	60	9	N/A	N/A	N/A
6/30/2020	64	9	9	10	N/A
3/31/2020	77	12	N/A	N/A	N/A
12/31/2019	82	13	19	20	N/A
9/30/2019	83	13	N/A	N/A	N/A
6/30/2019	83	13	17	18	N/A
3/31/2019	85	15	N/A	N/A	N/A
12/31/2018	87	15	19	20	N/A
9/30/2018	88	16	N/A	N/A	N/A
6/30/2018	91	17	18	19	N/A
3/31/2018	93	18	N/A	N/A	N/A
12/31/2017	95	20	N/A	16	N/A
9/30/2017	96	21	N/A	N/A	N/A
6/30/2017	98	22	N/A	15	N/A
3/31/2017	98	22	N/A	N/A	N/A
12/31/2016	98	23	N/A	16	N/A
9/30/2016	98	23	N/A	N/A	N/A
6/30/2016	98	23	N/A	23	N/A
3/31/2016	96	23	N/A	N/A	N/A
12/31/2015	96	23	N/A	21	N/A
9/30/2015	96	23	N/A	N/A	N/A
6/30/2015	96	23	N/A	22	N/A
3/31/2015	96	23	N/A	N/A	N/A
12/31/2014	96	23	N/A	25	N/A
12/31/2013	60	9	N/A	7	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei NTH ( 2.3% per jaar) ligt boven de spaarquote ( 1.8% ).

Winst versus markt: De winst van NTH ( 2.3% per jaar) zal naar verwachting langzamer groeien dan de markt Spanish ( 9% per jaar).

Hoge groeiwinsten: De winst van NTH zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van NTH ( 2% per jaar) zal naar verwachting langzamer groeien dan de markt Spanish ( 4.9% per jaar).

Hoge groei-inkomsten: De omzet van NTH ( 2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen NTH zal naar verwachting over 3 jaar hoog zijn ( 33.1 %)

Naturhouse Health Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Some May Be Optimistic About Naturhouse Health's (BME:NTH) Earnings

First half 2024 earnings released: EPS: €0.097 (vs €0.12 in 1H 2023)

New minor risk - Financial data availability

Investor sentiment deteriorates as stock falls 16%

Upcoming dividend of €0.081 per share

Now 20% overvalued after recent price rise

Now 21% overvalued after recent price rise

Now 20% overvalued after recent price rise

Upcoming dividend of €0.041 per share

Now 20% overvalued

We Think Naturhouse Health's (BME:NTH) Solid Earnings Are Understated

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Market cap size

Now 20% undervalued

New minor risk - Financial data availability

Upcoming dividend of €0.041 per share at 5.7% yield

New minor risk - Financial data availability

Now 20% undervalued after recent price drop

Upcoming dividend of €0.041 per share at 5.7% yield

Now 21% undervalued

Full year 2022 earnings released: EPS: €0.16 (vs €0.22 in FY 2021)

Now 20% undervalued

Calculating The Fair Value Of Naturhouse Health, S.A. (BME:NTH)

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Naturhouse Health (BME:NTH) Has A Pretty Healthy Balance Sheet

First half 2022 earnings released: EPS: €0.11 (vs €0.081 in 1H 2021)

Less than half of directors are independent

Upcoming dividend of €0.16 per share

Full year 2021 earnings: EPS and revenues miss analyst expectations

Naturhouse Health, S.A. (BME:NTH) acquired 24.8% stake in ICHEM Sp. z o.o. from Zamodiet Sa for €3.2 million.

What Does Naturhouse Health, S.A.'s (BME:NTH) Share Price Indicate?

Second quarter 2021 earnings released: EPS €0.081 (vs €0.02 in 2Q 2020)

Upcoming dividend of €0.049 per share

What Does Naturhouse Health, S.A.'s (BME:NTH) Share Price Indicate?

Is Naturhouse Health (BME:NTH) A Risky Investment?

Can Mixed Fundamentals Have A Negative Impact on Naturhouse Health, S.A. (BME:NTH) Current Share Price Momentum?

Full year 2020 earnings released: EPS €0.16 (vs €0.22 in FY 2019)

Revenue misses expectations

A Look At The Intrinsic Value Of Naturhouse Health, S.A. (BME:NTH)

Investor sentiment improved over the past week

New 90-day high: €1.69

Third quarter 2020 earnings released: EPS €0.064

Would Shareholders Who Purchased Naturhouse Health's (BME:NTH) Stock Five Years Be Happy With The Share price Today?

Market bids up stock over the past week

New 90-day high: €1.47

Market bids up stock over the past week

New 90-day low: €1.17

First half earnings released

New 90-day low - €1.32

New 90-day low - €1.41

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven